Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes-Reference-Cited by-同舟云学术

Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes

Published:2015-08-26 Issue:11 Volume:38 Page:e182-e183
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Gaudy Caroline¹²,Clévy Céline¹,Monestier Sandrine¹,Dubois Noémie³,Préau Yanis³,Mallet Stéphanie¹,Richard Marie-Aleth¹²,Grob Jean-Jacques¹²,Valéro René³⁴⁵,Béliard Sophie³⁴⁵⁶

Affiliation:

1. Departments of Dermatology and Oncology, La Timone Hospital, Assistance Publique–Hôpitaux de Marseille, Marseille, France

2. INSERM, UMRS 911, Marseille, France

3. Department of Nutrition, Metabolic Diseases and Endocrinology, La Conception Hospital, Assistance Publique–Hôpitaux de Marseille, Marseille, France

4. Faculty of Medicine, Aix-Marseille University, Marseille, France

5. INSERM, UMR 1062, Marseille, France

6. Institut National de la Recherche Agronomique, UMR 1260, Marseille, France

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/38/11/e182/623387/dc151331.pdf

Reference5 articles.

1. Fulminant type 1 diabetes—an important subtype in East Asia;Imagawa;Diabetes Metab Res Rev,2011

2. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014